GigaGen and Trianni Announce License Agreement for Discovery of Fully Human Immuno-Oncology Antibodies
GigaGen Inc., a biopharmaceutical company with patented technology for discovery of antibody therapeutics from millions-diverse immune repertoires, today announced a strategic partnership with Trianni, Inc., a biotechnology company that has developed novel mouse strains genetically engineered to express human antibodies. The partnership will use GigaGen technology to discover immuno-oncology antibody therapeutics through The Trianni Mouse platform.
Read the full press release.